Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

Bruker announced a bioRxiv preprint in which Charité researchers used timsTOF mass spectrometry to map a draft atlas of the human plasma proteome, detecting 5,077 protein groups across 179,049 distinct proteoforms. The workflow combined intact-protein fractionation with diaPASEF mass spectrometry on Bruker systems, producing a high-confidence map of 44,083 proteoforms without nanoparticle-based enrichment. Bruker executives framed the study as validating its timsTOF and new timsOmni platforms for proteoform-level biomarker and drug-target discovery, a demand driver for its life-science instruments.

•19d ago

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

Bruker announced new timsUltra AIP and timsOmni proteomics workflows at the Human Proteome Organization World Congress 2026, spanning deeper sequence coverage, discovery-to-validation, glycopeptide characterization, and RNA/DNA analysis. The MultiDIA-PASEF method yielded roughly 350,000 peptides per Parkinson's brain sample, identifying about 14,500 protein isoforms across more than 10,000 canonical proteins. Bruker also signed a co-marketing and development agreement with Affipro Analytics for integrated HDX-MS structural proteomics workflows. CEO Frank Laukien framed the announcements as building richer multimodal training data for next-generation biological AI models in drug discovery.

•27d ago

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

Bruker (Nasdaq: BRKR) received a multi-system order from the University of California, Berkeley for high-field NMR instrumentation at the Pines Magnetic Resonance Center, with the order exceeding $6 million and delivery expected in 2027. The investment centers on a Bruker AV NEO-X 800 MHz spectrometer equipped with a cryogenically cooled MAS CryoProbe, complemented by additional NMR systems supporting solid-state, solution-state, and Dynamic Nuclear Polarization research. The deal is financially small for Bruker but serves as a marquee reference win at a flagship magnetic resonance institution, reinforcing the company's leadership in high-field NMR and DNP technologies.

•1mo ago

BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

Bruker's deep-tech segment BEST (Bruker Energy & Supercon Technologies) and Luvata Materials & Solutions announced a strategic collaboration to supply high-performance RRP superconductors for magnetic confinement fusion projects worldwide. The partnership targets rapidly growing demand from next-generation fusion demonstration plants and first-of-a-kind power plants, aiming to significantly upscale global manufacturing capacity and strengthen supply-chain flexibility. RRP is an advanced niobium-tin wire technology rated for 12 to 20 Tesla fields, already proven in CERN's LHC, ITER, and the Wendelstein 7-X stellarator. Gauss Fusion is evaluating RRP for its Gauss Industrial Demonstrator and GIGA fusion power plant platform, giving the collaboration a concrete pipeline of prospective customers. No financial terms, volumes, or revenue contribution were disclosed, limiting near-term P&L visibility for Bruker.

•1mo ago

Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories

Bruker announced an expanded strategic collaboration with Atinary Technologies, including a minority investment, to advance self-driving laboratories and AI-driven R&D. The partnership integrates Atinary's SDLabs agentic AI platform with Bruker's Chemspeed automation, analytical instruments, and SciY software to enable closed-loop experimental workflows. The companies have established a joint demonstration laboratory in Basel, Switzerland, and are utilizing Atinary's lab in Boston to accelerate discovery in pharmaceuticals and materials science.

•2mo ago

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and human tissue models, to expand its disease biology and drug discovery solutions. The acquisition integrates MIMETAS' OrganoPlate platform with Bruker's existing proteomics, metabolomics, NMR, and spatial biology technologies to support advanced microphysiological systems. MIMETAS will continue to operate under its established brand and management, though financial details of the transaction were not disclosed.

•2mo ago

Bruker Reports Second Quarter 2026 Financial Results

Bruker reported Q2 2026 revenue of $838.5 million, up 5.2% year-over-year, driven by a 10% organic increase in bookings for its Scientific Instruments segment. Non-GAAP EPS grew to $0.49 and operating margin expanded to 14.1%, while GAAP results reflected a $134.9 million non-cash goodwill impairment charge resulting in a loss per share of $(0.41). The company updated its FY26 guidance for currency and tax impacts, maintaining revenue expectations of $3.54 to $3.57 billion and non-GAAP EPS of $2.10 to $2.15.

•2mo ago

BRKR: 8-K · dividend

Bruker Corporation declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend is payable on September 1, 2026, to shareholders of record at the close of business on August 15, 2026. The Board of Directors made the declaration on July 30, 2026.

SEC 8-K•2mo ago

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood

Bruker Corporation acquired the DISQVER clinical metagenomics platform from Noscendo GmbH to expand its next-generation sequencing (NGS) infection detection capabilities. The platform enables metagenomic analysis directly from cell-free blood samples, detecting over 11,000 different microbes and parasites in less than 24 hours. Financial details of the transaction were not disclosed, and the acquisition is not expected to be material to Bruker’s FY26 financial results.

•3mo ago

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

Bruker showcased its expanding Microbiology & Infection Diagnostics portfolio at ASM Microbe 2026, highlighting new FDA-cleared capabilities for the MALDI Biotyper CA System and new RUO/GP solutions for the U.S. market. The company reported robust demand in its U.S. microbiology business, citing 140 new system placements in 2025 and double-digit consumables growth that has continued into 2026. Bruker also introduced new workflows for rapid antimicrobial susceptibility testing and next-generation sequencing, aiming to accelerate clinical decision-making for sepsis and bloodstream infections.

•4mo ago

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

Bruker launched the timsMRMS mass spectrometry platform at ASMS, combining Trapped Ion Mobility Spectrometry with extreme-resolution Magnetic Resonance Mass Spectrometry. The system targets ultra-complex mixture applications in the energy industry, specifically for petroleomics, sustainable fuels, and advanced energy storage research. It offers mass resolution exceeding 10 million and sub-parts-per-million accuracy, enabling detailed molecular characterization of lithium-ion battery electrolytes and bio-oils.

•4mo ago

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

Bruker announced a suite of new mass spectrometry systems and software at ASMS, including the timsMRMS for ultra-high-resolution analysis and the timsOmni for top-down proteoform characterization. The company highlighted performance breakthroughs, such as identifying over 10,000 proteins per sample and achieving 4x sensitivity improvements for structural analysis. Bruker also confirmed a multi-million-dollar order from a leading global memory manufacturer for its TOFWERK semiconductor solutions, validating its industrial expansion strategy.

•4mo ago

Bruker Reports First Quarter 2026 Financial Results

Bruker reported Q1 revenue of $823.4 million, up 2.7% year-over-year, though organic revenue declined 4.4% due to US academic demand softness and FX headwinds. Despite the revenue pressure, non-GAAP EPS of $0.31 exceeded expectations, bolstered by a 3rd consecutive quarter of book-to-bill ratios above 1.0x in the Scientific Instruments segment. Management reconfirmed full-year FY26 guidance, projecting revenue of $3.57-$3.60 billion and non-GAAP EPS of $2.10-$2.15, implying double-digit EPS growth and a return to organic revenue growth in Q2.

•5mo ago